Navigation Links
Studies Confirm Balloon Sinuplasty(TM) Helps Chronic Sinusitis Patients

Research Verifies Technology Is Safe, Patient-Friendly, Economical

MENLO PARK, Calif., April 14 /PRNewswire/ -- Two independent studies published this week in American Journal of Rhinology and Annals of Otology, Rhinology, & Laryngology confirm Balloon Sinuplasty(TM) technology safely opens narrow sinuses, is economical and highly satisfactory to chronic sinusitis patients. The peer-reviewed studies analyzed outcomes of more than 1,100 individuals treated with this minimally-invasive balloon technology from Acclarent, a leading developer of innovative medical technologies for ear, nose and throat surgeons.

Chronic sinusitis is an inflammation of the nasal sinuses afflicting an estimated 37 million Americans annually. Symptoms include facial pain or pressure, nasal discharge, difficulty breathing through the nose, and fatigue. Although antibiotics and topical steroids can help many people, approximately 500,000 U.S. patients undergo surgery each year to alleviate the symptoms of chronic sinusitis.

Balloon Sinuplasty(TM) technology is similar in concept to catheters used in the heart for balloon angioplasty. The specially designed devices are threaded into the sinus passageways and gently inflated, widening the passages to promote drainage and resolution of chronic sinusitis symptoms. The technology can be used alone or with standard surgical instrumentation.

Recovery times vary but patients typically return to normal activities within 24 hours of treatment. Since 2005, more than 2,500 sinus surgeons have been trained on this technology and treated more than 25,000 patients.

Studies Confirm Balloon Sinuplasty(TM) Benefits

Patients who underwent sinus surgery using Balloon Sinuplasty(TM) technology were more satisfied, felt better post-operatively and experienced less pain, according to data published in the current issue of American Journal of Rhinology. The 70 patient study also showed the total cost of these procedures was similar or lower for patients when compared with traditional surgical instrumentation.

"Our aim is to provide long lasting relief for our chronic sinusitis patients in a way that is more satisfying and less painful to recover from than the traditional surgical technique. Now we have a proven solution that allows us to provide this level of care with out additional cost in selected patients. This technique can be performed under local anesthesia and minimizes risk to the patients," said lead author and surgeon Michael Friedman, M.D., of The Advanced Center for Specialty Care in Chicago.

Separate data in the April 2008 issue of Annals of Otology, Rhinology, & Laryngology also concluded Balloon Sinuplasty(TM) instrumentation is safe and effective. More than 95 percent of the study's 1,036 patients enjoyed sinus symptom improvement over an average follow-up of 40 weeks and no adverse events were attributable to Balloon Sinuplasty(TM).

On behalf of the 34 surgeons who took part in the Annals study, Dr. Howard Levine, director of the Cleveland Nasal, Sinus and Sleep Center said, "The results from this study reinforce the outstanding safety record of Balloon Sinuplasty(TM) technology, and underscore its effectiveness in alleviating chronic sinusitis symptoms. Results were universally excellent across a large population of patients and dozens of different practices."

Bill Facteau, President and CEO of Acclarent, Inc., said, "These data further confirm the safety, efficacy, and high patient satisfaction that have previously been published in other studies on Balloon Sinuplasty(TM). The multiple investigators of these papers have also demonstrated the cost effectiveness and reported on the economic advantages to the healthcare system when using this established tool in sinus surgery."

About Acclarent

Acclarent, Inc. is a privately held medical device company in Menlo Park, CA that was established in June of 2004. Its singular focus is improving patient care in all areas of otolaryngology by developing and producing medical devices solely for Ear, Nose and Throat (ENT) specialists and their patients. Acclarent is demonstrating this by investing in innovative technologies, clinical studies, and physician training. The company received FDA clearance to market Balloon Sinuplasty(TM) technology in early 2005. For more information, visit

SOURCE Acclarent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. Studies Prove Exercise Can Heal the Body Mind and Soul
6. Studies Shed New Light on Breast Cancer, Treatment
7. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: